"Given Gilead's current market valuation just under $100 billion, and AstraZeneca's astonishing $140 billion valuation, it's no surprise that investors were champing at the bit at the prospect of what would be the largest ever pharma merger."
#Stocks 
https://t.co/Bk6CVT4ck1